The FDA has cleared LumosityRx to improve attention function in adults aged 22 to 55 years with primarily inattentive or combined-type ADHD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback